Coming soon.

Therapeutic: Coming soon.

AiM Medical Robotics (Worcester, MA, USA) is commercializing an MRI-compatible surgical robot enabling intelligent intraoperative surgical planning and guidance utilizing “real-time” imaging. This is important for addressing brain shift causing target movement relative to the skull resulting in a 34% removal/revision rate for DBS placement. AiM's first product is for image-guided stereotactic neurosurgery and based on 15+ years and $15M of NIH-funded research. AiM’s approach overcomes many challenges associated with efficient, accurate, safe intracranial placement of neuromodulation, ablation, biopsy, and drug delivery.

Therapeutic: Robotics; Neurosurgery

AMT (The Netherlands, Ede, Gelderland and Utrecht, Utrecht) is a clinical-stage medical device company. AMT developed a minimally invasive alternative to traditional open heart bypass surgery (CABG). Surgeons perform open heart bypass procedures without opening the chest or stopping the heart, reducing patient recovery times and minimizing complications. The donor vessel is connected with a clip. A laser is used to create the opening between the vessels. This approach eliminates the need for a heart-lung machine and sutures, making the procedure less invasive and more standardized.

Therapeutic: Medical device; Cardiovascular

ArthroSave (Culemburg, The Netherlands) is a Dutch orthopedics company which has developed a unique solution to improve osteoarthritic joints, allowing patients to return to an active way of life. The CE-certified KneeReviver has demonstrated significant pain reduction, functional improvement and cartilage regeneration across multiple clinical studies. The long term data show that the KneeReviver treatment postpones the knee replacement with 10 more years. Gearing up for the next step, ArthroSave is raising EUR 5M to fund its commercialization in Europe, with the option to increase the investment to enable US market access. Currently, we are actively speaking with investors to realize this round and are keen to discuss our proposition with you in more detail. Are you available for a call on short term to discuss this?

Therapeutic: Orthopedics

Atmo's (Melbourne VIC, Australia and San Diego CA, USA) ingestible gas sensing capsule platform provides clinicians and patients with insights into gut health and dysfunction, aiming to offer relief and answers to the millions of people sufferering from common and debilitating functional gut disorders.

Therapeutic: Gastroenterology; Digital Health, Drug Delivery, Diagnostics

With the C-MIC Device - Berlin Heals (Zug, Switzerland) has developed an innovative, disruptive and easily implantable low-invasive microcurrent therapeutic device that has demonstrated tremendous clinical effects never seen before in heart failure patients.

Therapeutic: Cardiovascular; Heart Failure

Bluedrop Medical (Galway, Ireland) uses AI and Remote Patient Monitoring to predict and prevent diabetic foot ulcers - a 100k amputation, $17B problem annually in the US.

Therapeutic: Remote Patient Monitoring; Wound Care

CD Leycom (Hengelo, The Netherlands) develops medical devices for continuous, real-time assessment of cardiac function. Utilizing proprietary conductance catheterization technology, high-fidelity volume and pressure signals are captured simultaneously enabling direct, real-time ventricular pressure-volume loop monitoring. PV loops are widely recognized as the ‘Gold Standard’ of cardiac performance, providing over 50 quantitative hemodynamic measures related to cardiac energetics, compliance, contractility, and efficiency.

Therapeutic: Diagnostics

Cerhum (Liège, Belgium) produces patient-specific, 3D-printed biomaterial bone grafts and implants. We developed - and patented - a new generation of implant porosity optimised for vascularisation and superior osteoconductivity, offering a strongly differentiated alternative to autografts and traditional PSIs. Our initial focus is on maxillofacial and intra-oral (preimplantation) indications. Cerhum's solution MyBone is the closest possible alternative to an autograft, thanks to outstanding osseoconductivity properties, but without harvesting (and donor site morbidities), with a better predictability of patient outcomes and with faster surgeries

Therapeutic: Surgery; Maxillofacial

MithraX from CorQuest MedTech (Louvain-la-Neuve, Belgium) effectively addresses structural mitral regurgitation (MR) while also preventing functional MR. By preserving the native structures and dynamics of the mitral apparatus, it enhances the expected survival rate. MithraX offers a versatile solution suitable for various patient profiles and types of structural regurgitation.

Therapeutic: Cardiovascular

Chronic subdural hematomas (cSDH) are recurring collection of blood on the brain’s surface and their surgical drainage is the most common neurosurgical procedure in the US (>60,000/y). Endovascular Horizons (San Francisco, California, USA) has developed an entirely new class of endovascular technology capable of achieving trans-vascular access to the brain surface and evacuate cSDH. This technology, protected by multiple granted patents and supported by robust clinical data, is the first neurointerventional device purposed to puncture arteries and access the intracranial space to perform medical procedures.

Therapeutic: Neurovascular

We are a Dublin-based medtech company specialising in innovative, high-impact devices addressing unmet needs in pediatric cardiology, with significant potential in the adult market. Following the successful completion of pre-clinical studies, we anticipate securing a US patent for our device and method. Our €7M Series A raise will fund development through FDA clearance and US market launch within two years. Leveraging Ireland’s medtech infrastructure, we aim to create groundbreaking IP while delivering substantial commercial returns for stakeholders.

Therapeutic: Cardiovascular; Paediatric Cardiology, Congenital Heart Defects

INBRAIN Neuroelectronics (Barcelona, Spain) is pioneering real time precision neurologiy with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation.

Therapeutic: Brain Computer Interfaces/neuromodulation/bioelectronics

At IQ Endoscopes (Chepstow, South Wales), we are on a mission to drive rapid early diagnosis. Our sterile, single use endoscopes, designed and built in Great Britain, have been created to help more clinicians, help more patients around the world in a more sustainable way.

Therapeutic: Diagnostic and Therapeutic Endoscopy

Laminate Medical Technologies (Tel Aviv, Israel) is committed to advancing arteriovenous fistula (AVF) function for hemodialysis patients globally. Laminate's flagship product, VasQ™, is an extravascular support device designed to improve surgical fistula outcomes by providing permanent reinforcement to the artery-vein connection, promoting stability against wall tension, and decreasing turbulent flow. To learn more about creating more functional fistulas, visit https://www.laminatemedical.com/.

Therapeutic: Cardiovascular; Dialysis Access

LEM Surgical (Bern, Canton of Bern, Switzerland) is a robotics company founded in 2021 and based in Bern, Switzerland. Our mission is to become the leading robotic assistive technology provider for all hard tissue surgeries. Dynamis is the multi-arm, instrument-agnostic system that is the company's flagship product.

Therapeutic Category: Robotics; Orthopedics

Microsure’s (Son, Noord Brabant, the Netherlands) MUSA robot enables microsurgeons to operate at the very edge of human capabilities: performing anastomosis procedures to suture sub-millimeter blood vessels, lymphatic vessels as well as nerves with unparalleled precision and quality. Target surgeons: plastic and reconstructive surgeons. Target patients: breast reconstruction and lymphedema patients.

Therapeutic: Surgery; Microsurgery

NIMBLE Diagnostics (Barcelona, Spain) has developed a groundbreaking non-invasive, non-ionizing microwave-based technology to diagnose and monitor any issue with any metallic implant in the body. Our first indication focuses on coronary stents, where we have completed our first-in-human trial (15 patients), demonstrating strong correlation (R=0.82) with angiography (OCT) and a 100% accurate diagnosis according to clinical guidelines. Additionally, we have validated WTP, health economics, and reimbursement pathways in the US, Spain, and Germany, preparing our Series A of 15M€.

Therapeutic: Diagnostics; Cardiovascular

Panda Surgical (London, UK), a University College London spinout, is introducing the first ever dexterity-enhancing neurosurgical robotic platform, to make these operations safer, more effective, and more widely adopted. Deploying a series of interchangeable 3mm-diameter wristed instruments actuated by a smart handheld controller, our novel robotic system allows neurosurgeons to access confined spaces deep within the skull and spine and perform previously impossible delicate manoeuvres to manipulate tissue safely and precisely.

Therapeutic: Robotics; Neurosurgery, Spine, ENT

Perfuze (Galway, Ireland) is a medical device company that has developed novel catheter-based technology that has the potential to extract the entire clot from the brain of stroke patients in a single pass. Perfuze has raised €54m to date and has just completed its pivotal US IDE clinical study.

Therapeutic: Stroke

Plio Surgical (Dublin, Ireland) developed an innovative magnetic device for gastrointestinal surgery. Utilizing flexible silicone rings with patented tissue gripping features, it eliminates the need for sutures or staples to join the bowel after a resection. The rings pass naturally leaving no foreign body behind, which leads to better outcomes for patients. Plio addresses a significant unmet need for less invasive surgical solutions for conditions like colon cancer, Crohn’s disease and bariatric surgery.

Therapeutic: Minimally invasive surgery; Gastrointestinal surgery

Scandinavian Real Heart AB (Västerås, Sweden) is a preclinical-stage medical device company developing a total artificial heart as an alternative to heart transplantation for end-stage heart failure patients. The Realheart® TAH provides physiological cardiac output utilizing sensors and an algorithm to automatically match the body’s needs. The device is based on 20+ years of research, and has been awarded the EIC Accelerator and FDA HUD designation. Preclinical results show better blood-handling vs the market leading device and more adaptiveness to exercise and sleep.

Therapeutic: Cardiovascular

Rebrain (Pessac - Aquitaine - France) service assist neurosurgeon targeting for patient suffering from severe parkinson & essential tremor requiring surgical DBS solution of lesioning with HIFU/radiosurgery.

Therapeutic: Artificial intelligence; Neurostimulation planing service

Resolve Stroke is a Paris-based HealthTech company. We transform ultrasound into life-saving biomarkers by developing AI-powered software that extract significantly more information from raw data, enabling diagnostics previously deemed impossible. Our first focus is in neurology, aiming to accelerate diagnostics and treatments for over 1 billion people affected by brain diseases.

Therapeutic: Imaging

Scinvivo (Eindhoven, The Netherlands) Forward looking OCT imaging platform for in-vivo and realtime tissue depth structure imaging to support cancer diagnostics and treatment.

Therapeutic: In-vivo imaging

Sensars (Lausanne, Vaud, Switzerland) is pioneering neurostimulation to restore natural foot sensation in diabetic neuropathy patients, preventing ulcers and amputations. Our innovative system combines an implanted intraneural interface with a smart insole, delivering real-time sensory feedback. Existing solutions only manage pain or monitor walking but fail to address the root cause of ulcers—sensory loss in the feet. Sensars has received Breakthrough Device Designation and secured €3.5M in grants.

Therapeutic: Neuromodulation-Neurostimulation; Ulcer prevention

Implant free closure of a PFO is the holy grail for patients and cardiologists. Sigilla Medical (Dublin, Ireland) is developing a novel RF energy-based PFO closure system. With no implant the procedure’s risk profile will be improved. Sigilla Medical was founded by NLC Ventures, Robert Perryman and an international medtech company. Successful proof of concept has been completed in a chronic porcine model. The company is now raising €4m to buildout its team and initiate further pre-clinical testing by Dec 2025.

Therapeutic: Cardiovascular; Structural Heart

TEDIRO (Leipzig, Germany) is a category leader in healthcare robotics, addressing key challenges like labor shortages, rising costs, and quality care. With the introduction of THERY, the world’s first autonomous mobile robot certified as a medical device, TEDIRO’s platform approach enables robots to take on more therapeutic and diagnostic tasks, helping hospitals reduce costs, secure income, and attract patients seeking high-quality care.

Therapeutic: Artificial Intelligence; Orthopedics

“EVAR Is Only a Temporary Fix – AneuFix Makes It Last” Every year, over 200,000 patients undergo treatment for Abdominal Aortic Aneurysm (AAA), with more than 75% using EndoVAscular Repair (EVAR) by TripleMED (Geleen, the Netherlands) with stent grafts. EVAR has revolutionized aneurysm treatment, but its benefits fade over time. Within 10 years, 1 in 3 patients requires reintervention due to sac growth, endoleaks, or graft migration—driving up costs, hospital burden, and patient risk. What if EVAR could truly be a long-term solution? TripleMed’s AneuFix transforms EVAR by eliminating sac growth and preventing reinterventions, turning it into a first-time-right procedure. With proven clinical success, a clear regulatory path, and a $1.2B+ market opportunity, AneuFix is poised to reshape AAA treatment. Because good enough sometimes just isn’t good enough. We’re now seeking €13M to fund the pivotal RCT for US & EU expansion. If you’re ready to invest in the future of vascular innovation, let’s talk. 🔹 Stop Repeat Interventions | 🔹 Eliminate Sac Growth | 🔹 Make EVAR a First-Time-Right Solution

Therapeutic: Cardiovascular

Versono Medical Ltd. (Galway Ireland & Atlanta USA) was founded to transform the endovascular treatment of Complex Lesions and Total Occlusions (CTOs) through its disruptive FastWire platform technology. It can quickly cross severely blocked arteries to mediate and facilitate the treatment of complex lesions. FastWire has the potential to transform how Physicians approach and treat complex lesions in Critical Limb Threating Ischemic (CLTI) patients. Versono has completed Pilot, ongoing Pivotal Clinical studies, and advanced plans to commercialise and extend the clinical indications for FastWire.

Therapeutic: Cardiovascular

A medical sensor solutions company providing an implantable sensor system for wireless restenosis detection in the arteries. The system helps in diagnosing vessel clogging after stent implatation in real-time, on the basis of pulse wave velocity. Minimizing re-stenosis rates through affordable and frequent monitoring and enhancing cardiovascular patient outcomes globally. Creating a self-help community for cardiovascular patients on the basis of remote monitoring powered by VesselSens (Bonn, NRW, Germany).

Therapeutic: Remote Patient Monitoring; PAD: peripheral arterial disease; Stents and implantable sensors